Adaptive Designs in Clinical Trials conference


London, United Kingdom

We are proud to announce the 11th annual Adaptive Designs in Clinical Trials conference and exhibition will return to London from the 1st - 2nd April 2019. With the growing popularity in use and acceptance of adaptive designs in clinical trials - demonstrated most recently with the new  FDA  draft guidance on adaptive designs - there is a pressing need for a forum which explores this increasingly normalized medical methodology.

Hosting in depth presentations from regulatory agencies, researchers and biostatisticians, the meeting will cover how personalized medicine, platform trials, response-adaptive randomization, signature designs, estimand framework, bayesian methods and digital innovation are revolutionizing the drug development process both in Europe and North America.

Benefits of Attending

At this years conference there will once again be an array of networking opportunities:

  • Meet and network with key industry and thought leaders shaping state of the art adaptive design techniques
  • More than 4 hours of networking during the conference days
  • Engage with an array of vendors, with leading solution providers, Mevia and GCE Solutions among those exhibiting last year

Key reasons to attend:

  • See how the regulatory environment for adaptive drug design is shifting across the continent with insights from the MHRA, Amgen, AstraZeneca and Berry Consulting
  • Explore the therapeutic potential of  adaptive designs with real-world examples from H.Lundbeck, GSK Vaccines, Pfizer and Novartis
  • Listen to how the latest platform trial case studies - such as that of  the EPAD project and the MS Society  initiative, are impacting pharmaceutical development
  • Delve into the long-standing discussion of  Bayesian vs. frequentist designs
  • Discover the latest research in response-adaptive designs: trials for rare diseases and looking forward

Who should attend

  • Biostatisticians
  • Clinical project managers
  • Clinical research advisors
  • Clinical Trials Directors
  • Clinical scientists
  • Statisticians
  • Quantitative scientists

Plus Two Interactive Half-Day Post-Conference Workshops | Wednesday 3rd April 2019

Workshop A: The FDA - a new guidance on adaptive designs
Workshop Leader: Tom Parke, Director of Software Solutions, Berry Consulting
08.30 - 12.30

Workshop B: Design and analysis of clinical trials evaluating novel digital technologies
Workshop Leader: Alex Sverdlov, Director, Statistical Scientist, Novartis
Yevgen Ryeznik, PhD, Uppsala University
13.30 - 17.30

Speakers

  • Alex Sverdlov, Director, Statistical Scientist, Novartis
  • Andrea Callegaro, Senior Manager, Biostatistician, GSK Vaccines
  • Beatrice Panico, Medical Assessor , Medicines and Healthcare Products Regulatory Agency
  • Emma Gray, MS Society - Head of Clinical Trials, MS National Centre (MSNC)
  • Frank Fleischer, Team Leader Clinical Biostatistics, Boehringer-Ingelheim
  • Heiko Goette, Merck, Merck & Company
  • Kaspar Rufibach, Principal Statistical Scientist, F. Hoffman-La Roche AG
  • Macaulay Okwuokenye, Syros Pharmaceuticals, Principal Biostatistician, Syros Pharmaceuticals
  • Michael Proschan, Mathmatical Statistician, National Institute of Allergy and Infectious Diseases
  • Paul Frewer, Early Clinical Development, AstraZeneca
  • Philip Hougaard, Vice President, Biometrics, H. Lundbeck A/S
  • Sandeep Menon, Vice President, Pfizer Inc
  • Simon Wandel, Associate Director Statistical Methodologist, Novartis Pharmaceuticals
  • Sofia Villar, postdoctoral research associate , MRC Centre
  • Solange Corriol-Rohou, Senior Director Regulatory Affairs and Policy, EU, AstraZeneca
  • Tom Parke, Director of Software Solutions, Berry Consultants, LLP
  • Vladimir Anisimov, Principal Data Scientist, Amgen

Venue

Holiday Inn Kensington Forum
97 Cromwell Road
London, United Kingdom